193 related articles for article (PubMed ID: 17659962)
1. Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia.
Maia OO; Bonanomi MT; Takahashi WY; Nascimento VP; Takahashi BS
Am J Ophthalmol; 2007 Aug; 144(2):296-9. PubMed ID: 17659962
[TBL] [Abstract][Full Text] [Related]
2. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.
Charbel Issa P; Holz FG; Scholl HP
Ophthalmology; 2007 Sep; 114(9):1736-42. PubMed ID: 17822979
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma.
Song JH; Bae JH; Rho MI; Lee SC
Retina; 2010 Jun; 30(6):945-51. PubMed ID: 20531145
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II.
Kovach JL; Rosenfeld PJ
Retina; 2009 Jan; 29(1):27-32. PubMed ID: 18936721
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
[TBL] [Abstract][Full Text] [Related]
6. Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment.
Weinberger AW; Thiel M; Mohammadi B; Theofylaktopoulos I; Thumann G; Walter P
Am J Ophthalmol; 2007 Aug; 144(2):294-6. PubMed ID: 17659961
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
8. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema.
Soliman W; Vinten M; Sander B; Soliman KA; Yehya S; Rahman MS; Larsen M
Acta Ophthalmol; 2008 Jun; 86(4):365-71. PubMed ID: 18028237
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia.
Mandal S; Venkatesh P; Abbas Z; Vohra R; Garg S
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1825-9. PubMed ID: 17345090
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation.
Meyerle CB; Freund KB; Iturralde D; Spaide RF; Sorenson JA; Slakter JS; Klancnik JM; Fisher YL; Cooney MJ; Yannuzzi LA
Retina; 2007; 27(4):451-7. PubMed ID: 17420697
[TBL] [Abstract][Full Text] [Related]
11. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
[TBL] [Abstract][Full Text] [Related]
12. Disrupted foveal photoreceptors after combined cystoid spaces and retinal detachment in branch vein occlusion treated with bevacizumab.
Murakami T; Tsujikawa A; Miyamoto K; Sakamoto A; Ogino K; Muraoka Y; Kurashige Y; Yoshimura N
Retina; 2012 Oct; 32(9):1853-61. PubMed ID: 22481482
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis.
Jorge R; Costa RA; Calucci D; Scott IU
Graefes Arch Clin Exp Ophthalmol; 2007 Jul; 245(7):1045-8. PubMed ID: 17136357
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.
Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H
Curr Eye Res; 2010 Feb; 35(2):91-8. PubMed ID: 20136418
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of idiopathic juxtafoveolar retinal telangiectasis with bevacizumab (avastin)].
Schulze S; Mennel S
Klin Monbl Augenheilkd; 2007 Oct; 224(10):787-90. PubMed ID: 17952823
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
Chan WM; Lai TY; Liu DT; Lam DS
Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
